Proactive Investors - Run By Investors For Investors

Oncimmune receives regulatory approval from Israel for lung cancer diagnosis kit

Lung cancer kills more people in Israel than any other form of the disease, said the company.
Smokers at risk can by identified by Oncimmune

Oncimmune Holdings PLC (LON:ONC) has received regulatory approval to sell its early stage lung cancer detector, EarlyCDT-Lung, in Israel.

Lung cancer kills more people in Israel than any other form of the disease, said the company.

On an age-standardised basis, Israel's lung cancer mortality rate is 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region. 

Adam Hill, chief executive, added that the approval 'paves the way for the near-term commencement of commercial sales of EarlyCDT-Lung in the sophisticated healthcare market of Israel'. 

Oncimmune already has exclusive distribution agreements in numerous countries including Germany, France, Italy and Spain, while approval for an EarlyCDT-Lung kit was recently granted in Singapore.

View full ONC profile View Profile

Oncimmune Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
May 09 2019
Here we take a look under the hood of Shield Therapeutics

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use